Phaseline

Companies › Ardelyx

Ardelyx: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology, Gastroenterology, Respiratory; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tenapanor
Sodium/hydrogen exchanger 3 inhibitor
SLC9A3Phase 3Chronic Idiopathic Constipation (CIC); Cystic Fibrosis; SynucleinopathyFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06460038TenapanorPhase 2SynucleinopathyNeurologyDec 2026
NCT07382167TenapanorPhase 3Chronic Idiopathic Constipation (CIC)GastroenterologyFeb 2027
NCT06810167TenapanorPhase 3Cystic FibrosisRespiratoryJun 2027

From the company's SEC filings

Cash and short-term investments of $285m on 2026-09-30; operating cash outflow about $49m a year; runway about 70 months at that burn, to Jul 2032; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Targets

SLC9A3 (1)

Companies with the same targets

–

Companies built like this

Trevi Therapeutics Zydus Therapeutics GRIN Therapeutics Rapport Therapeutics Incannex Healthcare

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.